Prelude Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-196,905
| Closed | -$7.42M | – | 2170 |
|
|
2021
Q1 | $7.42M | Buy |
+196,905
| New | +$4.91M | 0.19% | 61 |
|
|
2019
Q3 | – | Sell |
-400
| Closed | -$2K | – | 2222 |
|
|
2019
Q2 | $2K | Buy |
+400
| New | +$3.82K | ﹤0.01% | 1588 |
|
|
2018
Q4 | – | Sell |
-906
| Closed | -$13K | – | 2311 |
|
|
2018
Q3 | $13K | Sell |
906
-1,208
| -57% | -$18K | ﹤0.01% | 1413 |
|
|
2018
Q2 | $33K | Buy |
2,114
+1,946
| +1,158% | +$34K | ﹤0.01% | 1242 |
|
|
2018
Q1 | $3K | Buy |
168
+29
| +21% | +$566 | ﹤0.01% | 1445 |
|
|
2017
Q4 | $3K | Sell |
139
-46
| -25% | -$1.48K | ﹤0.01% | 1297 |
|
|
2017
Q3 | $8K | Sell |
185
-9,330
| -98% | -$293K | ﹤0.01% | 1464 |
|
|
2017
Q2 | $286K | Buy |
9,515
+3,476
| +58% | +$108K | 0.03% | 470 |
|
|
2017
Q1 | $218K | Buy |
6,039
+4,939
| +449% | +$218K | 0.02% | 536 |
|
|
2016
Q4 | $55K | Sell |
1,100
-263
| -19% | -$13.8K | 0.01% | 1016 |
|
|
2016
Q3 | $72K | Sell |
1,363
-1,137
| -45% | -$54.3K | 0.01% | 926 |
|
|
2016
Q2 | $103K | Buy |
2,500
+700
| +39% | +$30.4K | 0.01% | 752 |
|
|
2016
Q1 | $73K | Buy |
+1,800
| New | +$61.9K | 0.01% | 862 |
|
|
2015
Q3 | – | Sell |
-2,500
| Closed | -$62K | – | 1906 |
|
|
2015
Q2 | $62K | Buy |
2,500
+300
| +14% | +$6.68K | 0.01% | 1079 |
|
|
2015
Q1 | $50K | Buy |
+2,200
| New | +$55.5K | 0.01% | 1286 |
|
|
2014
Q4 | – | Sell |
-3,100
| Closed | -$36K | – | 2247 |
|
|
2014
Q3 | $36K | Buy |
+3,100
| New | +$39.1K | 0.01% | 1531 |
|
Prelude Capital Management's FPRX Position: Q2 2021 in Review
Prelude Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 196,905 shares — an estimated $7.42M sold.
Prelude Capital Management first reported a position in FPRX in Q3 2014 and held it in 16 quarters. The position peaked at $7.42M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Prelude Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Prelude Capital Management sold 196,905 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $7.42M.
- Prelude Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 16 quarters.
- Prelude Capital Management's Five Prime Therapeutics, Inc. position peaked at $7.42M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.